News Search Results
Oct 15, 2025, 08:39 ET Sherak Launches Biotechnology-Based Luxury Skincare for Women 40+
skincare, combining scientific rigor and elegance to address the evolving skin needs of women's skin in midlife. Sherak, a biotechnology-driven luxury skincare company founded by chemist and former pharmaceutical executive Jennifer Sherak, today announced the official launch of its
More news about: Sherak Skin, LLC
Oct 15, 2025, 08:00 ET Monod Bio Receives Award to Develop a New Diagnostic Test for Preeclampsia using AI-designed Proteins
Monod Bio, a biotechnology company utilizing AI-powered de novo protein design for diagnostic and research applications, announced today that it has received a $750,000 grant
More news about: Monod Bio
Oct 15, 2025, 08:00 ET Ouro Medicines Announces Expansion of Clinical Development for OM336 in Sjögren's Disease and Idiopathic Inflammatory Myopathy
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2025 /PRNewswire/ -- Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic, immune-mediated diseases, today announced the initiation of a multinational
More news about: Ouro Medicines
Oct 15, 2025, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conferences
available for approximately 30 days following the events. ABOUT REGENXBIO Inc. REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Oct 15, 2025, 07:00 ET Origin Agritech Executes Northeast China Market Re-Entry with Product Showcase and Technology Seminar
Professor Feng Tian presented gene editing applications developed in collaboration with Origin, demonstrating the Company's continued innovation in biotechnology solutions. The Company launched its Golden Harvest Club and Brand Symbiosis Program in August, designed to strengthen dealer
More news about: Origin Agritech Limited
Oct 15, 2025, 07:00 ET Marengo Therapeutics to Present Key Pipeline Updates at 2025 SITC Annual Meeting and Reveal First Asset from TriSTAR™ Platform Targeting Nectin-4
CAMBRIDGE, Mass., Oct. 15, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision immunotherapy approaches in oncology and inflammation & immunology (I&I), today announced it will for the first
More news about: Marengo Therapeutics
Oct 15, 2025, 06:45 ET Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Oct 15, 2025, 06:30 ET Digital Health Market Size to Worth USD 2688 Billion by 2035 at 22.55% CAGR | Vantage Market Research
Public PayersPrivate Payers Patients & Consumers Pharmaceutical, Biotechnology, and MedTech Companies Other End Users
More news about: Vantage Market Research
Oct 14, 2025, 20:00 ET Nona Biosciences Appoints Dr. Di Hong as Chief Executive Officer to Drive Technology Innovation and Strategic Growth
CAMBRIDGE, Mass., Oct. 14, 2025 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced the appointment
More news about: Nona Biosciences
Oct 14, 2025, 15:31 ET Health and Wellness Food Market to Reach USD 2,177.10 billion by 2032, Growing At An 9.80% CAGR - Credence Research
Technological Innovation and Functional Food Development The integration of advanced food science, biotechnology, and nutritional research has catalyzed the development of sophisticated functional food products that deliver targeted health benefits beyond basic
More news about: Credence Research Inc.
Oct 14, 2025, 14:31 ET GCC Medical Tourism Market to Reach USD 889.97 million by 2032, Growing At An 10.26% CAGR - Credence Research
BIO International Convention, Saudi Arabia signed several memoranda of understanding between its leading health institutions and international biotechnology organizations. This includes a partnership between King Faisal Specialist Hospital and Research Center and US-based Germfree to localize the manufacturing
More news about: Credence Research Inc.
Oct 14, 2025, 10:15 ET Industrial Coatings Market Projected to Reach USD 142.99 Billion by 2035 with Rapid 3.95% CAGR | Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Oct 14, 2025, 09:00 ET Benchling Reveals the Next Chapter of R&D at Benchtalk 2025
"At Benchling, we are on a mission to unlock the power of biotechnology. Advances in AI will help our customers get life-saving medicines to patients faster," said Sajith Wickramasekara, CEO and co-founder of Benchling.
More news about: Benchling
Oct 14, 2025, 09:00 ET Benchling Reveals the Next Chapter of R&D at Benchtalk 2025
"At Benchling, we are on a mission to unlock the power of biotechnology. Advances in AI will help our customers get life-saving medicines to patients faster," said Sajith Wickramasekara, CEO and co-founder of Benchling.
More news about: Benchling
Oct 14, 2025, 08:31 ET MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference
CAMBRIDGE, Mass., Oct. 14, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that President and Chief Executive Officer, Hyung Heon Kim, will present
More news about: MetaVia Inc.
Oct 14, 2025, 08:30 ET Optimized Conjugation Solution for Precise Extrahepatic Delivery of Small Nucleic Acid Drug, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 14, 2025, 08:30 ET India's No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to launch 'Hyundai Hope for Cancer' to revolutionize Paediatric Cancer Care
to treatment for economically disadvantaged patients. The project is being headed by Prof. S. Mahalingam, Department of Biotechnology, IIT Madras. The Centre will further:
More news about: IIT Madras
Oct 14, 2025, 08:30 ET India's No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to launch 'Hyundai Hope for Cancer' to revolutionize Paediatric Cancer Care
to treatment for economically disadvantaged patients. The project is being headed by Prof. S. Mahalingam, Department of Biotechnology, IIT Madras. The Centre will further:
More news about: IIT Madras
Oct 14, 2025, 08:30 ET Liquid Class Optimization: Tips and Tricks for Efficiency and Reproducibility, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 14, 2025, 08:30 ET Smarter Site Feasibility Strategies for Predictable Enrollment in Late-Stage Oncology Trials, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 14, 2025, 08:30 ET Kyoto University Engineering Ph.D. Team Achieves Technology Transformation in Chengdu; LivingPhoenix's Biomimetic Collagen Rated "International Leading-Edge"
Takebayashi, Dr. Zhou Boyu, and Xie Hongbin. The related peer-reviewed paper was published in the SCI Q1 journal Frontiers in Bioengineering and Biotechnology in April 2025. The paper concluded that the biomimetic collagen component is safe, structurally stable, thermally stable, and demonstrates good
More news about: LivingPhoenix
Oct 14, 2025, 08:00 ET Rivus Pharmaceuticals to Present Clinical Data from Phase 2a M-ACCEL Trial of HU6 in MASH as Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025
cardiovascular disease. About Rivus PharmaceuticalsRivus Pharmaceuticals, Inc. is a clinical-stage biotechnology company advancing novel medicines for obesity and the resulting cardiometabolic diseases. A leader in mitochondrial biology, Rivus is developing
More news about: Rivus Pharmaceuticals
Oct 14, 2025, 08:00 ET BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process
receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about
More news about: BioVaxys Technology Corp.
Oct 14, 2025, 07:30 ET Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: Soligenix
Oct 14, 2025, 07:00 ET Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
Oct. 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.